Floatz logo

MOXIFLOXACIN

Cholangitis

Kangbuk Samsung HospitalSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
89/ 100

Competitive context

16 Active assets in the Cholangitis cohort.

Asset / SponsorPhaseRating
Ceftriaxone
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase 4BB
L-Ofloxacin
University of Southern California
Phase 4BB
NORMAL HUMAN SERUM ALBUMIN
EASL - CLIF Consortium
Phase 4BB
htd1801
HighTide Biopharma Pty Ltd
Phase 2B
Meperidine
National University of Malaysia
Phase 2B

View all 19 →

Same molecule, other indications

MOXIFLOXACIN is also rated in:

bacterial infectious disease with sepsisDormant
BB
Indicative ·
64 / 100
View asset →
Hodgkins lymphomaDormant
B
Indicative ·
62 / 100
View asset →
plasma cell myelomaDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →